CTMX

Piper Sandler Upgrades CytomX Therapeutics (CTMX)

Fintel reports that on May 28, 2024, Piper Sandler upgraded their outlook for CytomX Therapeutics (NasdaqGS:CTMX) from Neutral to Overweight.

Analyst Price Forecast Suggests 195.39% Upside

As of May 22, 2024, the average one-year price target for CytomX Therapeutics is 5.17. The forecasts range from a low of 2.27 to a high of $8.40. The average price target represents an increase of 195.39% from its latest reported closing price of 1.75.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for CytomX Therapeutics is 51MM, a decrease of 56.95%. The projected annual non-GAAP EPS is -0.83.

What is the Fund Sentiment?

There are 125 funds or institutions reporting positions in CytomX Therapeutics. This is an increase of 14 owner(s) or 12.61% in the last quarter. Average portfolio weight of all funds dedicated to CTMX is 0.06%, an increase of 58.23%. Total shares owned by institutions increased in the last three months by 33.39% to 45,381K shares. CTMX / CytomX Therapeutics, Inc. Put/Call Ratios The put/call ratio of CTMX is 0.06, indicating a bullish outlook.

What are Other Shareholders Doing?

CTMX / CytomX Therapeutics, Inc. Shares Held by Institutions

Bvf holds 6,596K shares representing 8.46% ownership of the company. No change in the last quarter.

Tang Capital Management holds 6,450K shares representing 8.28% ownership of the company. In its prior filing, the firm reported owning 6,550K shares , representing a decrease of 1.55%. The firm increased its portfolio allocation in CTMX by 56.06% over the last quarter.

Orbimed Advisors holds 3,545K shares representing 4.55% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.

Acadian Asset Management holds 2,691K shares representing 3.45% ownership of the company. In its prior filing, the firm reported owning 2,646K shares , representing an increase of 1.66%. The firm increased its portfolio allocation in CTMX by 28.48% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,182K shares representing 2.80% ownership of the company. No change in the last quarter.

CytomX Therapeutics Background Information
(This description is provided by the company.)

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, based on its Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.